Fmr LLC Acquires 72,033 Shares of Precigen, Inc. (NASDAQ:PGEN)

Fmr LLC raised its holdings in Precigen, Inc. (NASDAQ:PGEN) by 26.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 345,204 shares of the biotechnology company’s stock after acquiring an additional 72,033 shares during the quarter. Fmr LLC’s holdings in Precigen were worth $327,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Traphagen Investment Advisors LLC acquired a new position in shares of Precigen in the 3rd quarter valued at $29,000. SG Americas Securities LLC lifted its stake in Precigen by 44.2% in the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 13,823 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Precigen by 86.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock worth $52,000 after buying an additional 25,681 shares during the last quarter. AQR Capital Management LLC boosted its stake in Precigen by 56.7% during the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Precigen by 40.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 16,486 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Trading Up 5.1 %

Shares of NASDAQ PGEN opened at $0.76 on Friday. The company has a fifty day moving average price of $0.85 and a 200 day moving average price of $1.15. The firm has a market cap of $223.34 million, a PE ratio of -1.39 and a beta of 1.71. Precigen, Inc. has a 1-year low of $0.65 and a 1-year high of $1.93.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Precigen in a report on Friday, November 15th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Precigen currently has a consensus rating of “Hold” and an average target price of $7.00.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.